Kissei Pharmaceutical Co., Ltd.
Notice of Revision to Earnings Guidance
Revised the cumulative earnings guidance for the second quarter of the fiscal year ending March 2027. Net sales have been revised upward to 45,500 million yen (up 700 million yen, +1.6% vs. previous forecast), operating income revised upward to 1,600 million yen (up 1,100 million yen, +70.6%), ordinary income revised upward to 2,900 million yen (up 1,200 million yen, +70.6%), while interim net income attributable to owners of parent is revised to 5,100 million yen (down 2,300 million yen, -34.5%). The revisions reflect growth in new drugs and contributions from the information services business. The full-year outlook will be announced at the second quarter earnings announcement.
Key Figures
- Net Sales: 45,500 million yen
- Operating Income: 1,600 million yen
- Ordinary Income: 2,900 million yen
- Interim Net Income Attributable to Owners of Parent: 5,100 million yen
AI要約
Overview of Revision to Earnings Guidance
This document reports a revision to the earnings guidance for the cumulative second quarter of the fiscal year ending March 2027. Net sales are expected to exceed the previous forecast due to growth in new products and businesses, and operating income and ordinary income are raised based on increased gross profit and cost efficiency. Conversely, interim net income is reduced due to a forecasted extraordinary loss related to Tabneus-related assets.
Outlook and Points to Note
The full-year earnings guidance will be announced at the second quarter financial results release. Factors that may affect the full-year outlook include foreign exchange information, sales trends of new drugs and therapeutics, expansion of co-promotion expenses, and contributions from the information services business. Caution is required due to uncertainties such as administrative procedures and market trends that may affect realization.
Kissei Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
